#lynk-pharmaceuticals

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

Lynk Pharmaceuticals has reported positive long-term Phase III results for Zemprocitinib in treating moderate-to-severe rheumatoid arthritis. The results are a significant milestone for the company, demonstrating the efficacy and safety of its treatment. The positive results are expected to impact the company's stock price and future prospects.